MedTrace Logo

Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration

NCT06547242 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2024-08-09

No results posted yet for this study

Summary

Levothyroxine-sodium Bioequivalence Trial With Oral Single Dose Administration

Conditions

  • Healthy

Interventions

DRUG

Levothyroxin

Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence

DRUG

Levothyroxin

Single-dose administration of 600 mcg of Levothyroxin for the assessment of bioequivalence

Sponsors & Collaborators

  • Berlin-Chemie AG Menarini Group

    lead INDUSTRY

Principal Investigators

  • Warnke André, Dr. · SocraTec R&D GmbH

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-22
Primary Completion
2022-03-22
Completion
2022-05-22

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06547242 on ClinicalTrials.gov